Skip to main content

Table 5 Number of patients with periprocedural complications within 48 h

From: Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants

  Group A
Bridging
(n = 111)
Group B
VKA
(n = 318)
Group C
DOAC
(n = 351)
OR (95% CI)
p-value
A-B
OR (95% CI)
p-value
A-C
OR (95% CI)
p-value
B-C
Major complications 9 (8.1%) 8 (2.5%) 10 (2.8%) 3.42 (1.29–9.10)
0.019
3.01 (1.19–7.61)
0.025
1.14 (0.44–2.92)
0.816
 Major without cerebrovascular accidents 8 (7.2%) 5 (1.6%) 6 (1.7%) 4.86 (1.56–15.99)
0.006
4.466 (1.52–13.67)
0.007
1.09 (0.33–3.60)
1.0
  Major pericardial effusion 3 (2.7%) 2 (0.6%) 3 (0.9%) 4.39 (0.72–26.62)
0.112
3.22 (0.64–16.20)
0.153
1.36 (0.23–8.20)
1.0
  Major vascular 3 (2.7%) 3 (0.9%) 1 (0.3%) 2.92 (0.58–14.67)
0.182
9.72 (1.00–94.43)
0.045
0.30 (0.03–2.90)
0.351
 Cerebrovascular complications 1 (0.9%) 3 (0.9%) 4 (1.1%) 0.96 (0.10–9.27)
1.0
0.79 (0.09–7.13)
1.0
1.21 (0.27–5.45)
1.0
Minor complications 9 (8.1%) 24 (7.5%) 26 (7.4%) 1.08 (0.49–2.40)
0.838
1.10 (0.50–2.43)
0.837
0.98 (0.55–1.75)
1.0
 Minor pericardial effusion 0 (0.0%) 4 (1.3%) 7 (2.0%)
0.577

0.204
1.60 (0.46–5.51)
0.551
 Minor vascular complication 7 (6.3%) 16 (5.0%) 17 (4.8%) 1.27 (0.51–3.17)
0.627
1.32 (0.53–3.28)
0.623
0.96 (0.48–1.94)
1.0
 GI haemorrhage 0 (0.0%) 1 (0.3%) 0 (0.0%)
0.213

1.0

1.0
Groin haemorrhage 4 (3.6%) 4 (1.3%) 3 (0.9%) 2.94 (0.72–11.94)
0.066
4.34 (0.96–19.68)
0.060
0.68 (0.15–3.05)
0.714
 Major 2 (1.8%) 0 (0.0%) 1 (0.3%)
0.651
3.20 (0.45–23.00)
0.145
− 
0.50
 Minor 2 (1.8%) 4 (1.3%) 2 (0.6%) 1.44 (0.26–7.97)
0.019
6.42 (0.58–71.51)
0.245
0.22 (0.03–2.02)
0.196
  1. Legend: Bridging interrupted vitamin-K-antagonist, CI confidence interval, DOAC uninterrupted non-vitamin-K anticoagulants, OR odds ratio, VKA uninterrupted vitamin-K-antagonist